June 16, 2026 – The 24th CPhI China (World Pharmaceutical Raw Materials Exhibition) officially opened at the Shanghai New International Expo Centre, covering an exhibition area of 250,000 square meters and bringing together over 3,700 exhibitors from around the world. At this industry summit, the GOWELL Group (Chengdu GOWELL) chose to send a clear message to the global pharmaceutical supply chain through its full-spectrum API product matrix and a significantly expanded booth presence: platform-based supply capabilities are now in place, and the company is ready to engage deeply with the world.

On-Site Highlights: Full-Spectrum API Matrix on Display, with Booth Scale and Product Portfolio Upgraded in Tandem

At its CPhI booth, GOWELL systematically presented its API product portfolio covering multiple high-barrier varieties across various therapeutic areas, including iron isomaltoside, iron oxyhydroxide sucrose, sodium zirconium cyclosilicate, teprenone, beraprost sodium, omega‑3 fatty acid ethyl ester 90, and icosapent ethyl. In addition, the company showcased GalNAc-L96, a core raw material for small nucleic acid delivery, extending its business footprint into the upstream supply chain of nucleic acid drugs.

Behind this product matrix lies the company's comprehensive capability accumulation over more than two decades—from generic drug R&D to API manufacturing. GOWELL's core manufacturing site, GOWELL Pharmaceutical, has been designed, constructed, and operated in accordance with international GMP standards, and has established a complete production system covering both oral‑grade and injectable‑grade APIs. The fish oil API has obtained a Certificate of Suitability to the European Pharmacopoeia (CEP) issued by the European Directorate for the Quality of Medicines (Certificate No.: NO.CEP 2022-448-Rev 00), marking that its quality system has met EU-recognized standards and is qualified to compete internationally in high-barrier product categories.

From a generic drug company to an API platform, and from a single product to a full-spectrum portfolio, GOWELL is undergoing a strategic capability upgrade. The expansion of its CPhI booth is a tangible reflection of this structural transformation—as the integration of "APIs + formulated drugs" becomes a core competitive advantage in the context of volume-based procurement, GOWELL is responding to the global market's systemic demand for stable, compliant, and large-scale supply with a more comprehensive industrial chain capability.

Capability Restructuring: Value Upgrading from Single Product to Platform-Based Supply

In the current industry cycle, where global API competition is shifting from "price wars" to an integrated contest of "technology + services," mere production capacity is no longer sufficient to build a moat. GOWELL's strategy is to systematically transform its technical expertise and production capabilities into platform-based supply capabilities for the global market by building a full-spectrum API product matrix, sending a clear signal to pharmaceutical companies: "We can provide multiple API varieties consistently, stably, and in full compliance."

Through CPhI—a core matchmaking platform for the global pharmaceutical supply chain—GOWELL is able to establish direct technical and commercial dialogues with more international customers, gaining precise insights into market access requirements and capacity deployment needs in different regions. From traditional bulk APIs to high-barrier specialty products, and from chemical drug raw materials to core upstream materials for small nucleic acids, GOWELL's API product line is evolving from "single-point breakthroughs" to a "platform matrix." This concentrated presence at CPhI serves as a solid testament to how Chinese API companies are integrating into the global value chain with more complete and professional capability systems—while the industry is still searching for the next growth curve, GOWELL has already positioned itself as a trusted and stable participant in the global pharmaceutical supply chain.